Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma:: data from a multicentric Italian study and review of the literature

被引:193
作者
Fugazzola, L. [1 ]
Puxeddu, E.
Avenia, N.
Romei, C.
Cirello, V.
Cavaliere, A.
Faviana, P.
Mannavola, D.
Moretti, S.
Rossi, S.
Sculli, M.
Bottici, V.
Beck-Peccoz, P.
Pacini, F.
Pinchera, A.
Santeusanio, F.
Elisei, R.
机构
[1] Univ Milan, Inst Endocrine Sci, Milan, Italy
[2] IRCCS, Fdn Policlin, Milan, Italy
[3] Univ Perugia, Dept Internal Med, Perugia, Italy
[4] Univ Perugia, Endocrine Surg Reg Referral Ctr, Perugia, Italy
[5] Univ Pisa, Dept Endocrinol & Metab, Pisa, Italy
[6] Univ Perugia, Dept Pathol, Perugia, Italy
[7] Univ Pisa, Dept Oncol, Pisa, Italy
[8] Univ Milan, Osped San Paolo, Pathol Unit, Milan, Italy
[9] Univ Siena, Dept Internal Med, Siena, Italy
[10] Univ Siena, Dept Endocrinol & Metab, Siena, Italy
[11] Univ Siena, Dept Biochem, Siena, Italy
关键词
D O I
10.1677/erc.1.01086
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, a somatic point mutation of the B-RAF gene (V600E) has been identified as the most common genetic event in papillary thyroid carcinoma (PTC), with a prevalence variable among different series. Since discordant data on the clinico-pathologic features of B-RAF mutated PTC are present in the literature, the aim of the present co-operative study was to establish the prevalence of this genetic alteration and to perform a genotype-phenotype correlation in a large cohort of patients with PTC. To this purpose, a series of 260 sporadic PTCs with different histological variants were included in the study. The mutational analysis of the B-RAF gene was performed either by RT-PCR followed by single-stranded conformational polymorphism or by PCR and direct sequencing. Statistical analyses were obtained by means of chi(2)/Fisher's exact test and t-test. Overall, a heterozygous T > A transversion at nucleotide 1799 (V600E) was found in 99 out of 260 PTCs (38%). According to the histological type of the tumor, the B-RAF V600E mutation was present in 48.3% of cases of classic PTCs (85 out of 176), in 17.6% (nine out of 51) of follicular variants of PTCs, in 21.7% (five out of 23) in other PTC variants and in none of the ten poorly differentiated tumors. B-RAF(V600E) was significantly associated with the classic variant of PTC (P = 0.0001) and with an older age at diagnosis (P = 0.01). No statistically significant correlation was found among the presence of B-RAF(V600E) and gender, tumor node metastasis (TNM), multicentricity of the tumor, stage at diagnosis and outcome. In conclusion, the present study reports the prevalence of B-RAF(V600E) (38%) in the largest series of sporadic PTCs, including 260 cases from three different Italian referring centers. This prevalence is similar to that calculated by pooling together all data previously reported, 39.6% (759 out of 1914 cases), thus indicating that the prevalence of this genetic event lies around 38-40%. Furthermore, B-RAF(V600E) was confirmed to be associated with the papillary growth pattern, but not with poorer differentiated PTC variants. A significant association of B-RAF mutation was also found with an older age at diagnosis, the mutation being very rare in childhood and adolescent PTCs. Finally, no correlation was found with a poorer prognosis and a worse outcome after a median, follow-up of 72 months.
引用
收藏
页码:455 / 464
页数:10
相关论文
共 51 条
[1]  
American Joint Committee on Cancer - Thyroid, 2002, AJCC CANC STAG HDB, P89
[2]  
[Anonymous], 2004, World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Endocrine Organs
[3]  
[Anonymous], SURG PATHOLOGY THYRO
[4]   BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment [J].
Begum, S ;
Rosenbaum, E ;
Henrique, R ;
Cohen, Y ;
Sidransky, D ;
Westra, WH .
MODERN PATHOLOGY, 2004, 17 (11) :1359-1363
[5]  
Bongarzone I, 1998, CLIN CANCER RES, V4, P223
[6]   Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma [J].
Bongarzone, I ;
Fugazzola, L ;
Vigneri, P ;
Mariani, L ;
Mondellini, P ;
Pacini, F ;
Basolo, F ;
Pinchera, A ;
Pilotti, S ;
Pierotti, MA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (05) :2006-2009
[7]   Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAFV599Ins) [J].
Carta, C ;
Moretti, S ;
Passeri, L ;
Barbi, F ;
Avenia, N ;
Cavaliere, A ;
Monacelli, M ;
Macchiarulo, A ;
Santeusanio, F ;
Tartaglia, M ;
Puxeddu, E .
CLINICAL ENDOCRINOLOGY, 2006, 64 (01) :105-109
[8]   Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer [J].
Ciampi, R ;
Knauf, JA ;
Kerler, R ;
Gandhi, M ;
Zhu, ZW ;
Nikiforova, MN ;
Rabes, HM ;
Fagin, JA ;
Nikiforov, YE .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (01) :94-101
[9]   BRAF mutation in papillary thyroid carcinoma [J].
Cohen, J ;
Xing, MZ ;
Mambo, E ;
Guo, ZM ;
Wu, GG ;
Trink, B ;
Beller, U ;
Westra, WH ;
Ladenson, PW ;
Sidransky, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (08) :625-627
[10]   Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid:: A potential application for the preoperative assessment of thyroid nodules [J].
Cohen, Y ;
Rosenbaum, E ;
Clark, DP ;
Zeiger, MA ;
Umbricht, CB ;
Tufano, RP ;
Sidransky, D ;
Westra, WH .
CLINICAL CANCER RESEARCH, 2004, 10 (08) :2761-2765